{
  "symbol": "PM",
  "year": 2025,
  "Period": "Q1",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1624,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.241
  },
  "top_positive": [
    {
      "sent": "Swedish Match Notes Consent Solicitation and PMI Guarantee On June 15, 2023, our wholly owned subsidiary, Swedish Match AB (\"Swedish Match\"), initiated a public consent solicitation of eligible holders of certain outstanding series of its notes to amend certain terms and conditions of these respective notes\noutlook by major credit rating agencies were as follows: Short-term Long-term Outlook Moody\u2019s P-1 A2 Stable Standard\u00a0& Poor\u2019s A-2 A- Positive Fitch F1 A Stable 93 Table of Contents Revolving Credit Facilities At June\u00a030, 2025, our committed revolving credit facilities were as follows: Type (in billions) Committed Revolving Credit Facilities Multi-year $2.0 billion revolving credit, expiring February 10, 2026 (1) $ 2.0 Multi-year $2.5 billion revolving credit, expiring September 29, 2026 (2)  (3) 2.5 Multi-year \u20ac1.5 billion revolving credit, expiring January 29, 2028 1.8 Total facilities $ 6.3 (1) On January 28, 2022, we entered into an agreement, effective February 10, 2022, to amend and extend the term of our $2.0 billion multi-year revolving credit facility, for an additional year covering the period February 11, 2026 to February 10, 2027, in the amount of $1.9\u00a0billion.",
      "score": 0.9939
    },
    {
      "sent": "At June\u00a030, 2025, our credit ratings and outlook by major credit rating agencies were as follows: Short-term Long-term Outlook Moody\u2019s P-1 A2 Stable Standard\u00a0& Poor\u2019s A-2 A- Positive Fitch F1 A Stable 93 Table of Contents Revolving Credit Facilities At June\u00a030, 2025, our committed revolving credit facilities were as follows: Type (in billions) Committed Revolving Credit Facilities Multi-year $2.0 billion revolving credit, expiring February 10, 2026 (1) $ 2.0 Multi-year $2.5 billion revolving credit, expiring September 29, 2026 (2)  (3) 2.5 Multi-year \u20ac1.5 billion revolving credit, expiring January 29, 2028 1.8 Total facilities $ 6.3 (1) On January 28, 2022, we entered into an agreement, effective February 10, 2022, to amend and extend the term of our $2.0 billion multi-year revolving credit facility, for an additional year covering the period February 11, 2026 to February 10, 2027, in the amount of $1.9\u00a0billion.",
      "score": 0.9896
    },
    {
      "sent": "At June\u00a030, 2025, our credit ratings and outlook by major credit rating agencies were as follows: Short-term Long-term Outlook Moody\u2019s P-1 A2 Stable Standard\u00a0& Poor\u2019s A-2 A- Positive Fitch F1 A Stable 93 Table of Contents Revolving Credit Facilities At June\u00a030, 2025, our committed revolving credit facilities were as follows: Type (in billions) Committed Revolving Credit Facilities Multi-year $2.0 billion revolving credit, expiring February 10, 2026 (1) $ 2.0 Multi-year $2.5 billion revolving credit, expiring September 29, 2026 (2)  (3) 2.5 Multi-year \u20ac1.5 billion revolving credit, expiring January 29, 2028 1.8 Total facilities $ 6.3 (1) On January 28, 2022, we entered into an agreement, effective February 10, 2022, to amend and extend the term of our $2.0 billion multi-year revolving credit facility, for an additional year covering the period February 11, 2026 to February 10, 2027, in the amount of $1.9\u00a0billion.",
      "score": 0.9896
    }
  ],
  "top_negative": [
    {
      "sent": "In others, nationalization, terrorism, conflict and the threats of war or acts of war may have a significant impact on the business environment.",
      "score": -0.9493
    },
    {
      "sent": "This action initiated a scientific review of our MRTPAs which requested the following modified risk claim: \u201cUsing ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.\u201d During the review, the FDA will determine whether our applications provide the necessary evidence for ZYN products to be marketed with the requested claim.",
      "score": -0.9349
    },
    {
      "sent": "was authorized to market these products with the claim, \u201cUsing General snus instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.\u201d On November 7, 2024, the FDA renewed the General snus modified risk orders, with a stated expiration date in November 2032.",
      "score": -0.9349
    }
  ],
  "forward_snippets": [
    "However, we and our subsidiaries may enter into settlement discussions in particular cases if we believe it is in our best interests to do so.",
    "chewing tobacco (2) Includes chew bags and tobacco bits Note: Sum may not foot due to rounding Following the deconsolidation of our Canadian subsidiary, we continue to report the volume and corresponding royalty revenues of brands sold by RBH for which other PMI subsidiaries are the trademark owners.",
    "We continue to expect smoke-free product volume growth of 12% to 14%, partly offset by cigarette volume declines which we now forecast to be around 2%.",
    "We continue to expect 10 to 12% HTU adjusted IMS growth for the year, with growth skewed to the fourth quarter given a strong comparison in the third quarter.",
    "For the third quarter specifically, we forecast HTU shipments of 38.5 to 39.5 billion units."
  ],
  "curated_text": "Symbol: PM. Year: 2025. Period: Q1. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: Swedish Match Notes Consent Solicitation and PMI Guarantee On June 15, 2023, our wholly owned subsidiary, Swedish Match AB (\"Swedish Match\"), initiated a public consent solicitation of eligible holders of certain outstanding series of its notes to amend certain terms and conditions of these respective notes\noutlook by major credit rating agencies were as follows: Short-term Long-term Outlook Moody\u2019s P-1 A2 Stable Standard\u00a0& Poor\u2019s A-2 A- Positive Fitch F1 A Stable 93 Table of Contents Revolving Credit Facilities At June\u00a030, 2025, our committed revolving credit facilities were as follows: Type (in billions) Committed Revolving Credit Facilities Multi-year $2.0 billion revolving credit, expiring February 10, 2026 (1) $ 2.0 Multi-year $2.5 billion revolving credit, expiring September 29, 2026 (2)  (3) 2.5 Multi-year \u20ac1.5 billion revolving credit, expiring January 29, 2028 1.8 Total facilities $ 6.3 (1) On January 28, 2022, we entered into an agreement, effective February 10, 2022, to amend and extend the term of our $2.0 billion multi-year revolving credit facility, for an additional year covering the period February 11, 2026 to February 10, 2027, in the amount of $1.9\u00a0billion. At June\u00a030, 2025, our credit ratings and outlook by major credit rating agencies were as follows: Short-term Long-term Outlook Moody\u2019s P-1 A2 Stable Standard\u00a0& Poor\u2019s A-2 A- Positive Fitch F1 A Stable 93 Table of Contents Revolving Credit Facilities At June\u00a030, 2025, our committed revolving credit facilities were as follows: Type (in billions) Committed Revolving Credit Facilities Multi-year $2.0 billion revolving credit, expiring February 10, 2026 (1) $ 2.0 Multi-year $2.5 billion revolving credit, expiring September 29, 2026 (2)  (3) 2.5 Multi-year \u20ac1.5 billion revolving credit, expiring January 29, 2028 1.8 Total facilities $ 6.3 (1) On January 28, 2022, we entered into an agreement, effective February 10, 2022, to amend and extend the term of our $2.0 billion multi-year revolving credit facility, for an additional year covering the period February 11, 2026 to February 10, 2027, in the amount of $1.9\u00a0billion. At June\u00a030, 2025, our credit ratings and outlook by major credit rating agencies were as follows: Short-term Long-term Outlook Moody\u2019s P-1 A2 Stable Standard\u00a0& Poor\u2019s A-2 A- Positive Fitch F1 A Stable 93 Table of Contents Revolving Credit Facilities At June\u00a030, 2025, our committed revolving credit facilities were as follows: Type (in billions) Committed Revolving Credit Facilities Multi-year $2.0 billion revolving credit, expiring February 10, 2026 (1) $ 2.0 Multi-year $2.5 billion revolving credit, expiring September 29, 2026 (2)  (3) 2.5 Multi-year \u20ac1.5 billion revolving credit, expiring January 29, 2028 1.8 Total facilities $ 6.3 (1) On January 28, 2022, we entered into an agreement, effective February 10, 2022, to amend and extend the term of our $2.0 billion multi-year revolving credit facility, for an additional year covering the period February 11, 2026 to February 10, 2027, in the amount of $1.9\u00a0billion. Top negative sentences: In others, nationalization, terrorism, conflict and the threats of war or acts of war may have a significant impact on the business environment. This action initiated a scientific review of our MRTPAs which requested the following modified risk claim: \u201cUsing ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.\u201d During the review, the FDA will determine whether our applications provide the necessary evidence for ZYN products to be marketed with the requested claim. was authorized to market these products with the claim, \u201cUsing General snus instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.\u201d On November 7, 2024, the FDA renewed the General snus modified risk orders, with a stated expiration date in November 2032. Forward-looking snippets: However, we and our subsidiaries may enter into settlement discussions in particular cases if we believe it is in our best interests to do so. chewing tobacco (2) Includes chew bags and tobacco bits Note: Sum may not foot due to rounding Following the deconsolidation of our Canadian subsidiary, we continue to report the volume and corresponding royalty revenues of brands sold by RBH for which other PMI subsidiaries are the trademark owners. We continue to expect smoke-free product volume growth of 12% to 14%, partly offset by cigarette volume declines which we now forecast to be around 2%. We continue to expect 10 to 12% HTU adjusted IMS growth for the year, with growth skewed to the fourth quarter given a strong comparison in the third quarter. For the third quarter specifically, we forecast HTU shipments of 38.5 to 39.5 billion units."
}